158 related articles for article (PubMed ID: 32463779)
1. Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015.
Earla JR; Thornton JD; Hutton GJ; Aparasu RR
J Manag Care Spec Pharm; 2020 Jun; 26(6):741-749. PubMed ID: 32463779
[TBL] [Abstract][Full Text] [Related]
2. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
[TBL] [Abstract][Full Text] [Related]
3. Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data.
Zakeri M; Li J; Sansgiry SS; Aparasu RR
J Manag Care Spec Pharm; 2023 May; 29(5):480-489. PubMed ID: 37121258
[No Abstract] [Full Text] [Related]
4. Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programs.
Daniel GW; Malone DC
J Manag Care Pharm; 2007 Mar; 13(2):142-54. PubMed ID: 17330975
[TBL] [Abstract][Full Text] [Related]
5. Incremental Health Care Expenditure of Chronic Cutaneous Ulcers in the United States.
Tripathi R; Knusel KD; Ezaldein HH; Honaker JS; Bordeaux JS; Scott JF
JAMA Dermatol; 2019 Jun; 155(6):694-699. PubMed ID: 30892572
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Hua LH; Hersh CM; Morten P; Kusel J; Lin F; Cave J; Varga S; Herrera V; Ko JJ
J Manag Care Spec Pharm; 2019 Apr; 25(4):490-498. PubMed ID: 30917079
[TBL] [Abstract][Full Text] [Related]
7. Ophthalmic Medication Expenditures and Out-of-Pocket Spending: An Analysis of United States Prescriptions from 2007 through 2016.
Chen EM; Kombo N; Teng CC; Mruthyunjaya P; Nwanyanwu K; Parikh R
Ophthalmology; 2020 Oct; 127(10):1292-1302. PubMed ID: 32359935
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study.
Chinthammit C; Axon DR; Mollon L; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
J Manag Care Spec Pharm; 2021 Jan; 27(1):64-72. PubMed ID: 33377445
[No Abstract] [Full Text] [Related]
9. Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
Desai RJ; Mahesri M; Gagne JJ; Hurley E; Tong A; Chitnis T; Minden S; Spettell CM; Matlin OS; Shrank WH; Choudhry NK
J Manag Care Spec Pharm; 2019 Jan; 25(1):113-121. PubMed ID: 30589630
[TBL] [Abstract][Full Text] [Related]
10. Trends in the Concentration and Distribution of Health Care Expenditures in the US, 2001-2018.
Holle M; Wolff T; Herant M
JAMA Netw Open; 2021 Sep; 4(9):e2125179. PubMed ID: 34519767
[TBL] [Abstract][Full Text] [Related]
11. Incremental direct expenditure of treating asthma in the United States.
Kamble S; Bharmal M
J Asthma; 2009 Feb; 46(1):73-80. PubMed ID: 19191142
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden Associated with Receiving Inhaled Corticosteroids with Leukotriene Receptor Antagonists or Long-Acting Beta Agonists as Combination Therapy in Older Adults.
Altawalbeh SM; Thorpe CT; Zgibor JC; Kane-Gill S; Kang Y; Thorpe JM
J Manag Care Spec Pharm; 2018 May; 24(5):478-486. PubMed ID: 29694289
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013.
Bounthavong M; Li M; Watanabe JH
Res Social Adm Pharm; 2017; 13(3):530-538. PubMed ID: 27263802
[TBL] [Abstract][Full Text] [Related]
14. Differences in medical care expenditures for adults with depression compared to adults with major chronic conditions.
Lurie IZ; Manheim LM; Dunlop DD
J Ment Health Policy Econ; 2009 Jun; 12(2):87-95. PubMed ID: 19567934
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of cutaneous infections in children and adults with atopic dermatitis.
Sandhu JK; Salame N; Ehsani-Chimeh N; Armstrong AW
Pediatr Dermatol; 2019 May; 36(3):303-310. PubMed ID: 30968453
[TBL] [Abstract][Full Text] [Related]
16. Medical Expenditures Associated With Hypertension in the U.S., 2000-2013.
Zhang D; Wang G; Zhang P; Fang J; Ayala C
Am J Prev Med; 2017 Dec; 53(6S2):S164-S171. PubMed ID: 29153117
[TBL] [Abstract][Full Text] [Related]
17. Chronic condition combinations and health care expenditures and out-of-pocket spending burden among adults, Medical Expenditure Panel Survey, 2009 and 2011.
Meraya AM; Raval AD; Sambamoorthi U
Prev Chronic Dis; 2015 Jan; 12():E12. PubMed ID: 25633487
[TBL] [Abstract][Full Text] [Related]
18. The Economic Burden of Asthma in the United States, 2008-2013.
Nurmagambetov T; Kuwahara R; Garbe P
Ann Am Thorac Soc; 2018 Mar; 15(3):348-356. PubMed ID: 29323930
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
20. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
[No Abstract] [Full Text] [Related]
[Next] [New Search]
